ASP2905 is primarily investigated for its potential therapeutic applications in the field of neurology and psychiatry. It is being studied as a treatment for various central nervous system disorders, particularly those involving cognitive and mood regulation. Researchers are exploring its efficacy in conditions such as schizophrenia and bipolar disorder, where it may help modulate neurotransmitter activity to alleviate symptoms. Additionally, ASP2905 is being examined for its role in addressing neurodegenerative diseases, potentially offering neuroprotective benefits. Its mechanism of action targets specific pathways in the brain, making it a promising candidate for improving mental health outcomes. Clinical trials are ongoing to determine its safety, tolerability, and effectiveness in these applications.